Supporting Information

Iridium Supported on Porous Polypyridine-Oxadiazole as High Active and Recyclable Catalyst for Borrowing Hydrogen Reaction

Jiahao Li,^a Anruo Mao,^a Wei Yao,^a Haiyan Zhu,^a and Dawei Wang^{*a}

^a The Key Laboratory of Synthetic and Biological Colloids, Ministry of Education, School of Chemical and Material Engineering, Jiangnan University Wuxi 214122, Jiangsu Province, China.

E-mail: wangdw@jiangnan.edu.cn

Table of contents

1.	General methods and materials	.S2
2.	Preparation of PPO-Ir	
3.	Characterization of catalyst PPO-Ir	4-S5
4.	General procedure for 5 S	5
5.	General procedure for 7S	5-S6
6.	General procedure for 9S	6
7.	Hammett plot and mechanism studies	7
8.	Analytical data of the obtained compounds	21
9.	NMR spectra of obtained compounds S22-	S79
10.	. Reference	S80

1. General Methods and Materials

All the reactions dealing with air were carried out in a high purity argon or nitrogen atmosphere using standard Schlenk techniques or glovebox techniques. Unless the special instructions, all the reagents were provided from commercial suppliers (TCI, Acros, J&K, Energy Chemical, etc.) and used without further purification. All the obtained products were characterized by ¹H-NMR, ¹³C-NMR and referenced to CDCl₃ (7.26 ppm for ¹H, and 77.1 ppm for ¹³C) or DMSO- d_6 (2.50 ppm for ¹H, and 39.5 ppm for ¹³C) with tetramethylsilane as internal standard (0 ppm). ¹H-NMR and ¹³C-NMR spectra were obtained on Varian 400 or 101 MHz respectively on Bruker Advance III HD 400 MHz spectrometer. TEM was recorded on a transmission electron microscope (JEM-2100, JEOL, Japan), operating at 200 kV. SEM image and EDS spectra was performed on a HITACHI S-4800 field-emission scanning electron microscope. XPS data were recorded with electron energy analyzer (ESCALAB 250Xi, Thermo Fisher Co, USA). The nitrogen sorption isotherms and pore-size distribution curves were measured at the temperature of liquid nitrogen (77 K) by using an automatic volumetric adsorption equipment (Mircomeritics, ASAP2010). Thermogravimetric analysis was carried out using a TGA/DSC 1/1100SF instrument in dry nitrogen atmosphere at a heating rate of 10 °C/min from 50 to 650 °C. Inductively coupled plasma atomic emission spectroscopy (ICP-AES) analysis for Ir loading amount was determined by a Jarrell-Ash 1100 ICP-AES spectrometer.

2. Preparation of PPO-Ir

2.1 Procedure for synthesis of monomer 2¹



First, KOH (18 mmol) dissolved in ethanol (30 mL), and picolinohydrazide (18 mmol) was added until cooled to room temperature. Then CS_2 (27 mmol) was added into the mixture with a constant pressure dropping funnel. The resulting mixture was stirred at 80 °C for 11 h and

monitored by TLC until complete disappearance of picolinohydrazide. After completion of the reaction, the solution was removed under vacuum. Remaining mixture was added deionized water (40 mL) and was adjusted to pH=3 with hydrochloric acid. At this point, a great deal of yellow solids (1) was precipitated with a Brinell funnel (56% yield).



1 (3 mmol) and 1-iodo-4-vinylbenzene (3.6 mmol) were dissolved in DMF (9 mL) and added a mixture of CuI (0.15 mmol), 1,10-phenanthroline (0.3 mmol) and K₂CO₃ (3.9 mmol) were dissoved in DMF (9 mL) in advance. The mixture was stirred at 120 °C for 10 h, the reaction mixture was added water and extracted with ethyl acetate (3×50 mL). The organic phases were concentrated by removing the solvent under vacuum. Finally, the residue was purified by column chromatography with petroleum ether/ethyl acetate (petroleum ether /ethyl acetate = 5:1) as eluent to give the monomer **2** (78% yield).

2.2 Procedure for synthesis of PPO-Ir



The PVP (33.4 mg), and isopropanol (12 mL) were separately weighed into a 50 mL Schlenk bottle, fully dissolved, and heated to 70 ° C under nitrogen. Then the monomer **2** (645 mg) and AIBN (2.5 mg) were added to the Schlenk tube sequentially under vigorous stirring. Before cooling to ambient temperature, the polymerization was allowed to proceed for 24 h. The desired supported (PPO) was synthesized as a yellowish solid by centrifugal suspension and washed with EtOH in ultrasonic vibration for several times.



Under N₂ atmosphere, PPO (1.0 g), $[Cp*IrCl_2]_2$ (80 mg, 0.1 mmol) and dry methanol (5 mL) was added to an oven-dried 25 mL Schlenk tube equipped with a stir bar. Then, the tube was closed and the resulting mixture was stirred at room temperature for 12 h. After the reaction, the solid changed from white to yellow and the volume became clear. Solids were obtained by centrifugation and washed with methanol and dichloromethane three times each before dried to give the desired product **PPO-Ir**.

3. Characterization of catalyst PPO-Ir

Figure S1 showed SEM EDS image of **PPO-Ir** (a), and corresponding elemental mapping images of (b) C, (c) N, (d) O, (e) S, (f) Ir, which revealed iridium complex was supported on PPO successfully.



Figure S1. SEM EDS image of **PPO-Ir** (a), and corresponding elemental mapping images of (b) C, (c) N, (d) O, (e) S, (f) Ir.

Table.S1. Quantitative elemental composition of C, O, N and Ir from the PPO-Ir XPS data.

Nama	Start	Peak	End	Height	FWHM	Area (P)	Area (N) TPP-	Atomic %	
Iname	BE	BE	BE	CPS	eV	CPS.eV	2M		
N1s	408	399.37	394	20297.54	1.42	34617.76	312.72	12.81	
Ir4f	70	62.2	58	3858.18	1.51	11797.73	10.4	0.43	
O1s	540	534.48	526	10326.78	1.51	29631.38	172.25	7.05	
C1s	296	284.56	281	70796.11	1.52	138836.17	1946.52	79.71	

Thermogravimetric results showed that the synthesized heterogeneous iridium catalyst was very stable below 300 °C (Figure S2).



Figure S2. TG pattern of PPO-Ir.

4. General procedure for 5



To 25 mL Schlenk tube was added PPO-Ir (10 mg, 4.35% loading, w/w), 2-methyl-2-butanol (1.0 mL) and KOH (0.5 equiv.). Then **4** (0.5 mmol), **3** (0.75 mmol) were added and the mixture was stirred at 110 °C for 12 h. After the reaction mixture was cooled to room temperature, the reaction mixture was extracted with ethyl acetate three times. The organic phases were dried over anhydrous MgSO₄ and concentrated by removing the solvent under vacuum to give a crude product. The crude product was purified by column chromatography, eluting with petroleum ether/ethyl acetate to afford the desired product **5**.

5. General procedure for 7



To 25 mL Schlenk tube was added PPO-Ir (10 mg, 4.35% loading, w/w), 2-methyl-2-butanol (1.0 mL) and KOH (0.5 equiv.). Then **6** (0.5 mmol), **3** (0.75 mmol) were added and the mixture was stirred at 120 °C for 12 h. After the reaction mixture was cooled to room temperature, the reaction mixture was extracted with ethyl acetate three times. The organic phases were dried over anhydrous MgSO₄ and concentrated by removing the solvent under vacuum to give a crude product. The crude product was purified by column chromatography, eluting with petroleum ether/ethyl acetate to afford the desired product **7**.

6. General procedure for 9



To 25 mL Schlenk tube was added PPO-Ir (10 mg, 4.35% loading, w/w), TBAB (0.1 equiv.), water (1.0 mL) and KOH (0.5 equiv.). Then **8** (0.5 mmol), **3** (0.75 mmol) were added and the mixture was stirred at 100 °C for 16 h. After the reaction mixture was cooled to room temperature, the reaction mixture was extracted with ethyl acetate three times. The organic phases were dried over anhydrous MgSO₄ and concentrated by removing the solvent under vacuum to give a crude product. The crude product was purified by column chromatography, eluting with petroleum ether/ethyl acetate to afford the desired product **9**.

7. Hammett plot and mechanism studies



Experimental procedure: To 25 mL reaction tube was added dimethyl-6-aminouracil (0.5 mmol), corresponding benzyl alcohol (0.75 mmol), catalyst **PPO-Ir** (10 mg, 4% loading, w/w), KOH (0.75 equiv.). Then, 2-methyl-2-butanol (1.0 mL) were added and the mixture was stirred at 110 °C for 0.1 h. The solvent was removed under reduced pressure carefully and purification of the crude product by column chromatography on silica-gel (petroleum ether/ethyl acetate = 1:1) afforded the compound **5**. Next, the yield of product **5** was determined by GC.

R	OMe Me		Н	F	CF ₃	
Yield	28%	20%	18%	12%	8%	

Kinetic plot of benzyl alcohol and benzyl alcohol $-d_2$.



Experimental procedure: To 25 mL reaction tube was added dimethyl-6-aminouracil (0.5 mmol), benzyl alcohol-*d*2 or benzyl alcohol (0.75 mmol), catalyst **1a** (10 mg, 4% loading, w/w), KOH (0. 5 equiv.). Then, 2-methyl-2-butanol (1.1 mL) were added and the mixture was stirred at 110 °C. The yield of **3a**-*d*2 or **3a** was determined by NMR.

Time	0 h	1.5 h	3.0 h	4.5 h	6.0 h	7.5 h
Concentration of 3a (mol/L)	0.50	0.41	0.33	0.26	0.19	0.15
Concentration of $3a-d_2$ (mol/L)	0.50	0.46	0.42	0.37	0.32	0.28

8. Analytical data of the obtained compounds

(1)2-(pyridin-2-yl)-5-((4-vinylphenyl) thio)-1,3,4-oxadiazole (2).



Light yellow solid; Mp. 62-64 °C;¹H NMR (400 MHz, CDCl₃) δ 8.73 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 8.14 (dt, J = 7.9, 1.1 Hz, 1H), 7.84 (td, J = 7.8, 1.7 Hz, 1H), 7.63 (d, J = 8.4 Hz, 2H), 7.44 (d, J = 8.5 Hz, 3H), 6.69 (dd, J = 17.6, 10.9 Hz, 1H), 5.79 (d, J = 17.6 Hz, 1H), 5.32 (d, J = 10.9 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 165.38, 164.70, 150.29, 143.18, 139.31, 137.24, 135.66, 134.07, 127.50, 125.91, 125.40, 123.00, 115.99. HRMS Calculated for C₁₅H₁₂N₃OS [M+H]⁺ 282.0701, found 282.0700.

(2)6-(benzylamino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (5a)².



White solid; Mp. 149-150 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.37 – 7.24 (m, 5H), 5.61 (s, 1H), 4.79 (s, 1H), 4.22 (d, *J* = 5.2 Hz, 2H), 3.40 (s, 3H), 3.25 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 163.12, 153.06, 151.86, 136.11, 129.00, 128.14, 127.40, 76.11, 47.19, 28.85, 27.78.

(3)1,3-dimethyl-6-((4-methylbenzyl) amino) pyrimidine-2,4(1H,3H)-dione (5b)².



White solid; Mp. 136-138 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.16 (s, 4H), 5.36 (s, 1H), 4.83 (s, 1H), 4.18 (d, J = 5.0 Hz, 2H), 3.40 (s, 3H), 3.26 (s, 3H), 2.33 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 163.11, 152.92, 151.88, 138.09, 132.95, 129.69, 127.56, 76.10, 47.06, 28.78, 27.80, 21.12.

(4)6-((4-methoxybenzyl) amino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (5c)².



Light red solid; Mp. 176-177 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.25 – 7.16 (m, 2H), 6.96 – 6.81 (m, 2H), 5.20 (t, *J* = 5.0 Hz, 1H), 4.85 (s, 1H), 4.16 (d, *J* = 4.9 Hz, 2H), 3.79 (s, 3H), 3.40 (s, 3H), 3.27 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 163.08, 159.54, 152.85, 151.88, 129.02, 127.92, 114.39, 76.08, 55.35, 46.83, 28.77, 27.79.

(5)6-((4-chlorobenzyl) amino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (5d)².



White solid; Mp. 201-202 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.29 (d, J = 8.4 Hz, 2H), 7.19 (d, J = 8.4 Hz, 2H), 5.92 (s, 1H), 4.68 (s, 1H), 4.19 (d, J = 5.3 Hz, 2H), 3.43 (s, 3H), 3.24 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 163.15, 153.21, 151.75, 134.75, 133.80, 129.06, 128.60, 75.92, 46.35, 29.05, 27.80. **(6)6-((4-bromobenzyl)amino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (5e).**



Light yellow solid; Mp. 209-210 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.48 (d, J = 8.4 Hz, 2H), 7.16 (d, J = 8.3 Hz, 2H), 5.37 (s, 1H), 4.77 (s, 1H), 4.20 (d, J = 5.2 Hz, 2H), 3.42 (s, 3H), 3.27 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 163.03, 152.83, 151.78, 134.99, 132.18, 129.14, 122.17, 76.39, 46.66, 28.83, 27.86. HRMS Calculated for C₁₃H₁₅N₃O₂Br [M+H]⁺ 324.0348, found 324.0346.

(7)6-((4-fluorobenzyl) amino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (5f).



White solid; Mp. 167-168 °C; ¹H NMR (400 MHz, DMSO- d_6) δ 7.51 (s, 1H), 7.40 (dd, J = 8.2, 5.7 Hz, 2H), 7.17 (t, J = 8.8 Hz, 2H), 4.53 (s, 1H), 4.32 (d, J = 5.6 Hz, 2H), 3.37 (s, 3H), 3.07 (s, 3H).¹³C NMR (101 MHz, DMSO- d_6) δ 161.92, 161.75 (d, J = 242.6 Hz), 153.56, 151.91, 134.51 (d, J = 2.9 Hz), 129.27 (d, J = 8.1 Hz), 115.61 (d, J = 21.3 Hz), 74.88, 45.08, 29.79, 27.52. HRMS Calculated for C₁₃H₁₅N₃O₂F [M+H]⁺ 264.1148, found 264.1149.

(8) 6-((4-iodobenzyl)amino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (5g).



Light yellow solid; Mp. 181-183 °C; ¹H NMR (400 MHz, DMSO- d_6) δ 7.70 (d, J = 8.2 Hz, 2H), 7.50 (s, 1H), 7.17 (d, J = 8.2 Hz, 2H), 4.49 (s, 1H), 4.29 (d, J = 5.7 Hz, 2H), 3.36 (s, 3H), 3.06 (s, 3H).¹³C NMR (101 MHz, DMSO- d_6) δ 161.89, 153.52, 151.90, 138.31, 137.60, 129.69, 93.26, 74.95, 45.29, 29.81, 27.55. HRMS Calculated for C₁₃H₁₅N₃O₂I [M+H]⁺ 372.0209, found 372.0207.

(9) 6-(([1,1'-biphenyl]-4-ylmethyl)amino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (5h).



White solid; Mp. 199-200 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.60 – 7.53 (m, 4H), 7.44 (t, *J* = 7.5 Hz, 2H), 7.35 (dd, *J* = 15.7, 7.7 Hz, 3H), 5.29 (s, 1H), 4.86 (s, 1H), 4.25 (d, *J* = 4.9 Hz, 2H), 3.42 (s, 3H), 3.28 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 163.11, 152.96, 151.87, 141.20, 140.28, 134.96, 128.90, 127.99, 127.70, 127.63, 127.04, 76.25, 46.98, 28.85, 27.83. HRMS Calculated for C₁₉H₂₀N₃O₂ [M+H]⁺ 322.1556, found 322.1554.

(10) 1,3-dimethyl-6-((4-(trifluoromethyl) benzyl) amino) pyrimidine-2,4(1H,3H)-dione (5i)².



White liquid; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.71 (d, *J* = 8.1 Hz, 2H), 7.58 (d, *J* = 8.1 Hz, 3H), 4.51 (s, 1H), 4.44 (d, *J* = 5.6 Hz, 2H), 3.39 (s, 3H), 3.07 (s, 3H).¹³C NMR (101 MHz, DMSO-*d*₆) δ 161.91, 153.58, 151.91, 143.42, 128.37, 128.03, 125.73 (q, *J* = 3.7 Hz), 124.76 (d, *J* = 271.9 Hz), 74.97, 45.37, 29.82, 27.52.

(11) 1,3-dimethyl-6-((3-methylbenzyl) amino) pyrimidine-2,4(1H,3H)-dione (5j)².



White solid; Mp. 176-177 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.21 (t, J = 7.5 Hz, 1H), 7.12 – 7.02 (m, 3H), 5.78 (s, 1H), 4.77 (s, 1H), 4.17 (d, J = 5.2 Hz, 2H), 3.41 (s, 3H), 3.24 (s, 3H), 2.32 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 163.19, 153.22, 151.87, 138.71, 136.14, 128.82, 128.79, 128.03, 124.36, 75.86, 47.07, 28.95, 27.76, 21.41.

(12) 6-((3-methoxybenzyl) amino) -1,3-dimethylpyrimidine-2,4(1H,3H)-dione (5k).



Light yellow solid; Mp. 164-165 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.26 (d, J = 14.1 Hz, 1H), 6.90 – 6.79 (m, 3H), 5.50 (s, 1H), 4.80 (s, 1H), 4.20 (d, J = 4.9 Hz, 2H), 3.78 (s, 3H), 3.41 (s, 3H), 3.26 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 163.16, 160.08, 153.08, 151.84, 137.71, 130.09, 119.55, 113.49, 112.92, 76.08, 55.28, 47.08, 28.86, 27.78. HRMS Calculated for C₁₄H₁₈N₃O₃ [M+H]⁺ 276.1348, found 276.1349.

(13) 6-((3-chlorobenzyl)amino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (5l).



Light red solid; Mp. 176-177 °C;¹H NMR (400 MHz, CDCl₃) δ 7.31 – 7.28 (m, 3H), 7.20 – 7.13 (m, 1H), 5.36 (s, 1H), 4.79 (s, 1H), 4.24 (d, *J* = 5.3 Hz, 2H), 3.44 (s, 3H), 3.27 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 163.05, 152.84, 151.78, 138.07, 134.99, 130.36, 128.43, 127.42, 125.55, 76.45, 46.67, 28.84, 27.86. HRMS Calculated for C₁₃H₁₅N₃O₂Cl [M+H]⁺ 280.0853, found 280.0852.

(14) 6-((3-bromobenzyl)amino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (5m).



White solid; Mp. 184-185 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.45 (d, J = 9.0 Hz, 2H), 7.24 (d, J = 6.8 Hz, 2H), 5.10 (s, 1H), 4.81 (s, 1H), 4.25 (d, J = 5.2 Hz, 2H), 3.44 (s, 3H), 3.29 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 162.94, 152.72, 151.80, 138.28, 131.42, 130.65, 130.39, 126.06, 123.17, 76.59, 46.68, 28.80, 27.86. HRMS Calculated for C₁₃H₁₅N₃O₂Br [M+H]⁺ 324.0348, found 324.0350.

(15) 6-((3-fluorobenzyl) amino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (5n).



White solid; Mp. 158-160 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.53 (s, 1H), 7.39 (q, *J* = 7.4 Hz, 1H), 7.21 (d, *J* = 8.0 Hz, 2H), 7.09 (t, *J* = 8.2 Hz, 1H), 4.52 (s, 1H), 4.36 (d, *J* = 5.7 Hz, 2H), 3.38 (s, 3H), 3.07 (s, 3H).¹³C NMR (101 MHz, DMSO-*d*₆) δ 162.86 (d, *J* = 243.5 Hz), 161.94, 153.60, 151.91, 141.58 (d, *J* = 7.1 Hz), 130.83 (d, *J* = 8.3 Hz), 123.29 (d, *J* = 2.6 Hz), 114.27 (d, *J* = 21.1 Hz), 114.03 (d, *J* = 21.8 Hz), 74.90, 45.29, 29.80, 27.53. HRMS Calculated for C₁₃H₁₅N₃O₂F [M+H]⁺ 264.1148, found 264.1146.

(16) 1,3-dimethyl-6-((2-methylbenzyl)amino)pyrimidine-2,4(1H,3H)-dione (50)².



Light red solid; Mp. 188-189 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.26 – 7.17 (m, *J* = 4.1 Hz, 4H), 4.88 (s, 1H), 4.86 (s, 1H), 4.19 (d, *J* = 4.7 Hz, 2H), 3.39 (s, 3H), 3.28 (s, 3H), 2.33 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 163.04, 152.82, 151.86, 136.40, 133.60, 130.91, 128.51, 128.32, 126.51, 76.11, 45.55, 28.77, 27.81, 18.95.

(17) 6-((2-chlorobenzyl)amino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (5p).



Light red solid; Mp. 209-210 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.44 – 7.40 (m, 1H), 7.35 – 7.28 (m, 3H), 4.98 (s, 1H), 4.89 (s, 1H), 4.38 (s, 2H), 3.44 (s, 3H), 3.29 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 162.94, 152.58, 151.84, 133.64, 133.24, 130.12, 129.79, 129.74, 127.36, 76.44, 45.35, 28.63, 27.85. HRMS Calculated for C₁₃H₁₅N₃O₂Cl [M+H]⁺ 280.0853, found 280.0855.

(18) 6-((2-bromobenzyl)amino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (5q).



White solid; Mp. 210-211 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.60 (d, J = 7.9 Hz, 1H), 7.32 (d, J = 4.3 Hz, 2H), 7.22 (dt, J = 8.9, 4.5 Hz, 1H), 5.04 (s, 1H), 4.88 (s, 1H), 4.35 (d, J = 5.5 Hz, 2H), 3.44 (s, 3H), 3.29 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 162.99, 152.57, 151.84, 134.83, 133.39, 130.03, 129.92, 127.97, 123.62, 76.45, 47.62, 28.67, 27.86. HRMS Calculated for C₁₃H₁₅N₃O₂Br [M+H]⁺ 324.0348, found 324.0347.

(19) 6-((2-fluorobenzyl)amino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (5r).



White Liquid; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.46 (s, 1H), 7.43 – 7.30 (m, 2H), 7.26 – 7.16 (m, 2H), 4.54 (s, 1H), 4.37 (d, *J* = 5.7 Hz, 2H), 3.37 (s, 3H), 3.07 (s, 3H). ¹³C NMR (101 MHz, DMSO) δ 161.94, 160.51 (d, *J* = 244.3 Hz), 153.57, 151.89, 129.63 (d, *J* = 8.2 Hz), 129.49 (d, *J* = 4.1 Hz), 124.95 (d, *J* = 3.4 Hz), 124.90, 124.76, 115.68 (d, *J* = 21.1 Hz), 74.48, 29.83, 27.54. HRMS Calculated for C₁₃H₁₅N₃O₂F [M+H]⁺ 264.1148, found 264.1147.

(20) 6-((2-iodobenzyl)amino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (5s).



Light yellow solid; Mp. 184-185 °C; ¹H NMR (400 MHz, DMSO- d_6) δ 7.92 – 7.87 (m, 1H), 7.53 (s, 1H), 7.42 – 7.37 (m, 1H), 7.35 – 7.28 (m, 1H), 7.11 – 7.00 (m, 1H), 4.32 (s, 1H), 4.24 (d, J = 5.5 Hz, 2H), 3.40 (s, 3H), 3.08 (s, 3H).¹³C NMR (101 MHz, DMSO- d_6) δ 161.92, 153.57, 151.89, 139.61,

139.09, 129.80, 128.95, 128.36, 98.85, 74.96, 51.36, 29.92, 27.59. HRMS Calculated for $C_{13}H_{15}N_3O_2I$ [M+H]⁺ 372.0209, found 372.0208.

(21) 1,3-dimethyl-6-((3,4,5-trimethoxybenzyl)amino)pyrimidine-2,4(1H,3H)-dione (5t).

Light yellow solid; Mp. 185-186 °C;¹H NMR (400 MHz, DMSO- d_6) δ 7.44 (s, 1H), 6.70 (s, 2H), 4.60 (s, 1H), 4.24 (d, J = 5.7 Hz, 2H), 3.77 (s, 6H), 3.64 (s, 3H), 3.38 (s, 3H), 3.07 (s, 3H).¹³C NMR (101 MHz, DMSO- d_6) δ 161.99, 153.72, 153.44, 151.95, 136.95, 134.14, 104.75, 74.88, 60.41, 56.36, 46.13, 29.83, 27.53. HRMS Calculated for C₁₆H₂₂N₃O₅ [M+H]⁺ 336.1559, found 336.1558.

(22) 1,3-dimethyl-6-((thiophen-2-ylmethyl)amino)pyrimidine-2,4(1H,3H)-dione (5u).



Light red solid; Mp. 181-182 °C; ¹H NMR (400 MHz, DMSO- d_6) δ 7.54 (t, J = 5.7 Hz, 1H), 7.46 – 7.39 (m, 1H), 7.10 (d, J = 2.9 Hz, 1H), 6.98 (dd, J = 5.0, 3.5 Hz, 1H), 4.73 (s, 1H), 4.51 (d, J = 5.7 Hz, 2H), 3.31 (s, 3H), 3.07 (s, 3H).¹³C NMR (101 MHz, DMSO- d_6) δ 161.96, 153.42, 151.91, 141.84, 127.26, 126.19, 125.60, 75.01, 41.45, 29.83, 27.56. HRMS Calculated for C₁₁H₁₄N₃O₂S [M+H]⁺ 252.0807, found 252.0808.

(23) 1,3-dimethyl-6-((thiophen-3-ylmethyl)amino)pyrimidine-2,4(1H,3H)-dione (5v).



Red oil; ¹H NMR (400 MHz, CDCl₃) δ 7.34 (dd, J = 4.9, 3.0 Hz, 1H), 7.23 – 7.17 (m, 1H), 7.08 – 7.00 (m, 1H), 5.33 (s, 1H), 4.89 (s, 1H), 4.27 (d, J = 5.1 Hz, 2H), 3.41 (s, 3H), 3.28 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 163.24, 152.96, 151.84, 136.83, 127.14, 126.79, 123.11, 75.98, 42.57, 28.84, 27.85. HRMS Calculated for C₁₁H₁₄N₃O₂S [M+H]⁺ 252.0807, found 252.0809.

(24) 1,3-dimethyl-6-((naphthalen-2-ylmethyl)amino)pyrimidine-2,4(1H,3H)-dione (5w)².



White solid; Mp. 201-202 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (dd, J = 14.0, 8.7 Hz, 3H), 7.68 (s, 1H), 7.53 – 7.46 (m, 2H), 7.38 – 7.31 (m, 1H), 5.20 (s, 1H), 4.86 (s, 1H), 4.32 (d, J = 5.0 Hz, 2H), 3.39 (s, 3H), 3.27 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 163.03, 152.86, 151.83, 133.28, 133.01, 129.01, 127.79, 127.74, 126.69, 126.60, 126.45, 125.18, 76.30, 47.49, 28.78, 27.82.

(25) 1,3-dimethyl-6-((naphthalen-1-ylmethyl)amino)pyrimidine-2,4(1H,3H)-dione (5x)².



White solid; Mp. 209-210 °C; ¹H NMR (400 MHz, DMSO- d_6) δ 8.17 (d, J = 8.0 Hz, 1H), 8.04 – 7.94 (m, 1H), 7.91 – 7.82 (m, 1H), 7.64 – 7.51 (m, 3H), 7.52 – 7.46 (m, 2H), 4.80 (d, J = 5.5 Hz, 2H), 4.54 (s, 1H), 3.40 (s, 3H), 3.07 (s, 3H).¹³C NMR (101 MHz, DMSO- d_6) δ 161.96, 153.82, 151.97, 133.83, 132.91, 131.11, 129.10, 128.10, 126.77, 126.35, 125.89, 124.83, 123.68, 74.92, 44.16, 29.94, 27.55. **(26) 5-benzyl-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (7a)³.**



Light yellow solid; Mp. 93-94 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.26 – 7.21 (m, 3H), 7.06 – 7.00 (m, 2H), 3.78 (t, *J* = 4.7 Hz, 1H), 3.47 (d, *J* = 4.8 Hz, 2H), 3.13 (s, 6H).¹³C NMR (101 MHz, CDCl₃) δ 168.32, 151.01, 135.12, 128.87, 128.64, 127.87, 50.72, 37.93, 28.21.

(27) 1,3-dimethyl-5-(4-methylbenzyl)pyrimidine-2,4,6(1H,3H,5H)-trione (7b)³.



White Oil; ¹H NMR (400 MHz, CDCl₃) δ 7.02 (d, J = 7.9 Hz, 2H), 6.90 (d, J = 8.1 Hz, 2H), 3.75 (t, J = 4.8 Hz, 1H), 3.42 (d, J = 4.8 Hz, 2H), 3.12 (s, 6H), 2.28 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 168.42, 151.08, 137.50, 131.93, 129.30, 128.74, 50.79, 37.63, 28.20, 21.10.

(28) 1,3-dimethyl-5-(3-methylbenzyl)pyrimidine-2,4,6(1H,3H,5H)-trione (7c)³.



White solid; Mp. 92-93 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.11 (t, *J* = 7.5 Hz, 1H), 7.04 (d, *J* = 7.6 Hz, 1H), 6.86 – 6.78 (m, 2H), 3.75 (t, *J* = 4.8 Hz, 1H), 3.41 (d, *J* = 4.8 Hz, 2H), 3.11 (s, 6H), 2.27 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 168.43, 151.04, 138.33, 134.97, 129.52, 128.55, 128.45, 125.81, 50.77, 38.10, 28.11, 21.24.

(29) 5-(2-methoxybenzyl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (7d).



White solid; Mp.126-127 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.19 (td, J = 7.8, 1.8 Hz, 1H), 6.99 (dd, J = 7.5, 1.8 Hz, 1H), 6.86 – 6.74 (m, 2H), 3.74 (d, J = 5.6 Hz, 1H), 3.72 (s, 3H), 3.37 (d, J = 5.7 Hz, 2H), 3.07 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 168.51, 157.27, 151.55, 131.12, 129.03, 123.50, 120.36, 110.10, 55.14, 50.10, 33.31, 28.06. HRMS Calculated for C₁₄H₁₇N₂O₄ [M+H]⁺ 277.1188, found 277.1186.

(30) 5-(3-methoxybenzyl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (7e)⁴.



Yellow Oil; ¹H NMR (400 MHz, CDCl₃) δ 7.15 (dd, J = 8.3, 7.5 Hz, 1H), 6.77 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 6.63 – 6.56 (m, 2H), 3.76 (t, J = 4.7 Hz, 1H), 3.74 (s, 3H), 3.43 (d, J = 4.8 Hz, 2H), 3.14 (s, 6H).¹³C NMR (101 MHz, CDCl₃) δ 168.28, 159.73, 151.04, 136.66, 129.61, 121.12, 114.39, 113.30, 55.17, 50.60, 37.75, 28.22.

(31) 5-(3-fluorobenzyl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (7f)⁴.



Yellow Oil; ¹H NMR (400 MHz, CDCl₃) δ 7.24 – 7.15 (m, 2H), 7.09 (t, J = 1.8 Hz, 1H), 6.96 (dt, J = 7.3, 1.5 Hz, 1H), 3.78 (t, J = 4.8 Hz, 1H), 3.45 (d, J = 4.8 Hz, 2H), 3.18 (s, 6H).¹³C NMR (101 MHz, CDCl₃) δ 167.90, 162.72 (d, J = 247.0 Hz), 150.96, 137.92 (d, J = 7.3 Hz), 130.17 (d, J = 8.3 Hz), 124.71 (d, J = 2.9 Hz), 116.02 (d, J = 21.5 Hz), 114.74 (d, J = 21.1 Hz), 50.37, 36.57 (d, J = 1.9 Hz), 28.35.

(32) 5-(4-(tert-butyl)benzyl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (7g).



White Oil; ¹H NMR (400 MHz, CDCl₃) δ 7.29 (d, J = 8.3 Hz, 2H), 6.90 (d, J = 8.3 Hz, 2H), 4.03 (s, 1H), 3.25 (s, 2H), 3.11 (s, 6H), 1.28 (s, 9H).¹³C NMR (101 MHz, CDCl₃) δ 169.98, 151.66, 149.78,

128.92, 128.79, 125.41, 49.36, 34.55, 31.22, 28.53. HRMS Calculated for $C_{17}H_{23}N_2O_3$ [M+H]⁺ 303.1709, found 303.1707.

(33) 1,3-dimethyl-5-(3-(trifluoromethyl)benzyl)pyrimidine-2,4,6(1H,3H,5H)-trione (7h).



White solid; Mp.115-116 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.54 – 7.49 (m, 1H), 7.38 (t, J = 7.7 Hz, 1H), 7.35 (d, J = 1.9 Hz, 1H), 7.28 (dd, J = 7.0, 2.1 Hz, 1H), 3.82 (t, J = 4.7 Hz, 1H), 3.54 (d, J = 4.8 Hz, 2H), 3.15 (s, 6H).¹³C NMR (101 MHz, CDCl₃) δ 167.82, 150.80, 136.56, 132.51, 131.06 (q, J = 32.5 Hz), 129.11, 127.87 (q, J = 271.0 Hz), 125.82 (q, J = 3.7 Hz), 124.56 (q, J = 3.9 Hz), 50.37, 36.63, 28.28. HRMS Calculated for C₁₄H₁₄F₃N₂O₃ [M+H]⁺ 315.0907, found 315.0906.

(34) 1,3-dimethyl-5-(2-(trifluoromethyl)benzyl)pyrimidine-2,4,6(1H,3H,5H)-trione (7i).



Yellow Oil; ¹H NMR (400 MHz, CDCl₃) δ 7.68 – 7.62 (m, 1H), 7.55 – 7.48 (m, 1H), 7.41 – 7.34 (m, 2H), 3.80 (t, J = 7.0 Hz, 1H), 3.53 (dd, J = 7.1, 1.4 Hz, 2H), 3.27 (s, 6H).¹³C NMR (101 MHz, CDCl₃) δ 167.55, 151.52, 135.14, 131.88, 131.15, 128.89 (q, J = 29.9 Hz), 128.40 (q, J = 272.0 Hz), 127.42, 126.36 (q, J = 5.9 Hz), 50.73, 33.01 (q, J = 2.0 Hz), 28.66. HRMS Calculated for C₁₄H₁₄F₃N₂O₃ [M+H]+ 315.0907, found 315.0908.

(35) 1,3-dimethyl-5-(4-(trifluoromethyl)benzyl)pyrimidine-2,4,6(1H,3H,5H)-trione (7j)³.



Yellow Oil; ¹H NMR (400 MHz, CDCl₃) δ 7.51 (d, J = 8.6 Hz, 2H), 7.24 (d, J = 8.0 Hz, 2H), 3.82 (t, J = 4.9 Hz, 1H), 3.55 (d, J = 4.9 Hz, 2H), 3.19 (s, 6H).¹³C NMR (101 MHz, CDCl₃) δ 167.58, 150.87, 140.03, 130.38(q, J = 32.0 Hz), 129.64, 128.01 (q, J = 270.8 Hz), 125.54 (q, J = 3.7 Hz), 50.22, 35.58, 28.47.

(36) 5-(3,5-bis(trifluoromethyl)benzyl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (7k).



White solid; Mp.137-138 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.78 (s, 1H), 7.64 – 7.61 (m, 2H), 3.85 (t, J = 4.8 Hz, 1H), 3.62 (d, J = 4.8 Hz, 2H), 3.20 (s, 6H).¹³C NMR (101 MHz, CDCl₃) δ 167.23, 150.67,

138.67, 131.95 (q, J = 33.4 Hz), 129.68, 127.11 (q, J = 271.0 Hz), 121.59 (q, J = 4.0 Hz), 50.16, 35.07, 28.47. HRMS Calculated for $C_{15}H_{13}F_6N_2O_3$ [M+H]⁺ 383.0830, found 383.0827.

(37) 5-(benzo[d][1,3]dioxol-5-ylmethyl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (7l)³.



Yellow Oil; ¹H NMR (400 MHz, CDCl₃) δ 6.66 (d, J = 7.8 Hz, 1H), 6.55 – 6.48 (m, 2H), 5.92 (s, 2H), 3.73 (t, J = 4.7 Hz, 1H), 3.39 (d, J = 4.7 Hz, 2H), 3.17 (s, 6H).¹³C NMR (101 MHz, CDCl₃) δ 168.26, 151.12, 147.80, 147.09, 128.76, 122.24, 109.15, 108.33, 101.10, 50.79, 37.33, 28.28.

(38) 1,3-dimethyl-5-(naphthalen-2-ylmethyl)pyrimidine-2,4,6(1H,3H,5H)-trione (7m)³.



Green Oil; ¹H NMR (400 MHz, CDCl₃) δ 7.81 – 7.77 (m, 1H), 7.73 (dd, J = 9.0, 5.9 Hz, 2H), 7.56 – 7.52 (m, 1H), 7.48 – 7.43 (m, 2H), 7.15 (dd, J = 8.4, 1.9 Hz, 1H), 3.86 (t, J = 4.8 Hz, 1H), 3.64 (d, J = 4.8 Hz, 2H), 3.10 (s, 6H).¹³C NMR (101 MHz, CDCl₃) δ 168.29, 150.90, 133.32, 132.74, 132.64, 128.34, 127.99, 127.72, 127.60, 126.75, 126.42, 126.12, 50.74, 37.65, 28.28.

(39) 1,3-dimethyl-5-(thiophen-2-ylmethyl)pyrimidine-2,4,6(1H,3H,5H)-trione $(7n)^5$.



Orange solid; Mp.100-101 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.13 (dd, *J* = 5.1, 1.2 Hz, 1H), 6.88 (dd, *J* = 5.2, 3.4 Hz, 1H), 6.78 (dd, *J* = 3.6, 1.2 Hz, 1H), 3.73 (q, *J* = 3.2 Hz, 3H), 3.21 (s, 6H).¹³C NMR (101 MHz, CDCl₃) δ 167.82, 151.12, 136.57, 127.34, 127.07, 125.33, 50.52, 30.88, 28.48.

(40) 1,3-dimethyl-5-(thiophen-3-ylmethyl)pyrimidine-2,4,6(1H,3H,5H)-trione (70)⁵.



Yellow solid; Mp.128-129 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.22 (dd, J = 4.9, 3.0 Hz, 1H), 6.97 (dd, J = 3.1, 1.3 Hz, 1H), 6.77 (dd, J = 4.9, 1.3 Hz, 1H), 3.72 (t, J = 4.6 Hz, 1H), 3.52 (d, J = 4.6 Hz, 2H), 3.17 (s, 6H).¹³C NMR (101 MHz, CDCl₃) δ 168.26, 151.07, 135.34, 127.93, 126.30, 123.37, 50.27, 31.65, 28.34.

(41) 2-phenylquinazoline (9a)⁶.



White solid; Mp.237-238 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.39 (s, 1H), 8.54 (dd, J = 8.0, 1.8 Hz, 2H), 8.02 (d, J = 9.4 Hz, 1H), 7.87 – 7.80 (m, 2H), 7.56 – 7.51 (m, 1H), 7.49 – 7.39 (m, 3H).¹³C NMR (101 MHz, CDCl₃) δ 161.08, 160.55, 150.78, 138.03, 134.19, 130.66, 128.69, 128.66, 128.60, 127.33, 127.17, 123.62.

(42) 2-(m-tolyl)quinazoline (9b)⁶.



Yellow solid; Mp.99-100 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.45 (s, 1H), 8.42 (d, J = 11.4 Hz, 2H), 8.09 (d, J = 8.4 Hz, 1H), 7.89 (t, J = 8.0 Hz, 2H), 7.63 – 7.56 (m, 1H), 7.43 (t, J = 7.6 Hz, 1H), 7.32 (d, J = 7.5 Hz, 1H), 2.49 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 161.21, 160.50, 150.77, 138.33, 137.93, 134.17, 131.50, 129.15, 128.63, 128.61, 127.26, 127.17, 125.83, 123.59, 21.58.

(43) 2-(m-tolyl)quinazoline (9c)⁶.



White solid; Mp.98-99 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.38 (s, 1H), 8.44 (d, J = 8.2 Hz, 2H), 8.00 (s, 1H), 7.86 – 7.79 (m, 2H), 7.52 (t, J = 7.0 Hz, 1H), 7.27 (d, J = 7.9 Hz, 2H), 2.37 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 161.13, 160.50, 150.78, 140.95, 135.26, 134.14, 129.46, 128.55, 128.54, 127.17, 127.10, 123.52, 21.56.

(44) 2-(4-methoxyphenyl)quinazoline (9d)⁶.



White solid; Mp.87-88 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.39 (s, 1H), 8.60 – 8.54 (m, 2H), 8.02 (d, J = 8.9 Hz, 1H), 7.87 – 7.82 (m, 2H), 7.53 (t, J = 8.1 Hz, 1H), 7.06 – 7.01 (m, 2H), 3.88 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 161.85, 160.85, 160.41, 150.83, 134.03, 130.73, 130.24, 128.40, 127.14, 126.79, 123.32, 113.99, 55.40.

(45) 2-(4-(tert-butyl)phenyl)quinazoline (9e)⁶.



White solid; Mp.82-84 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.43 (s, 1H), 8.57 – 8.51 (m, 2H), 8.07 (dd, J = 8.3, 1.0 Hz, 1H), 7.90 – 7.84 (m, 2H), 7.59 – 7.54 (m, 3H), 1.38 (s, 9H).¹³C NMR (101 MHz, CDCl₃)

δ 161.15, 160.04, 153.97, 150.84, 135.33, 134.03, 128.62, 128.39, 127.13, 127.05, 125.65, 123.53, 34.91, 31.31.

(46) 2-(3-fluorophenyl)quinazoline (9f)⁷.



Yellow solid; Mp.95-97 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.43 (s, 1H), 8.41 (d, J = 7.8 Hz, 1H), 8.32 (d, J = 10.4 Hz, 1H), 8.07 (d, J = 8.1 Hz, 1H), 7.90 (t, J = 7.3 Hz, 2H), 7.61 (t, J = 7.5 Hz, 1H), 7.51 – 7.44 (m, 1H), 7.18 (dd, J = 8.3, 2.7 Hz, 1H).¹³C NMR (101 MHz, CDCl₃) δ 163.29 (d, J = 244.8 Hz), 160.56, 159.82 (d, J = 3.0 Hz), 150.64, 140.45 (d, J = 7.9 Hz), 134.30, 130.09 (d, J = 7.9 Hz), 128.68, 127.63, 127.16, 124.19 (d, J = 2.9 Hz), 123.75, 117.48 (d, J = 21.4 Hz), 115.41 (d, J = 23.4 Hz).

(47) 2-(4-fluorophenyl)quinazoline (9g)⁶.



Yellow solid; Mp.69-70 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.32 (s, 1H), 8.57 – 8.48 (m, 2H), 7.95 (d, *J* = 8.8 Hz, 1H), 7.85 – 7.74 (m, 2H), 7.49 (t, *J* = 7.0 Hz, 1H), 7.10 (t, *J* = 8.7 Hz, 2H).¹³C NMR (101 MHz, CDCl₃) δ 164.69 (d, *J* = 250.4 Hz), 160.52, 160.10, 150.71, 134.21, 130.73, 130.65, 128.55, 127.29, 127.15, 123.49, 115.57 (d, *J* = 21.6 Hz).

(48) 2-(4-chlorophenyl)quinazoline (9h)⁶.



White solid; Mp.133-134 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.38 – 9.31 (m, 1H), 8.52 – 8.44 (m, 2H), 7.98 (dt, *J* = 9.1, 1.0 Hz, 1H), 7.86 – 7.79 (m, 2H), 7.53 (ddd, *J* = 8.1, 7.0, 1.1 Hz, 1H), 7.45 – 7.38 (m, 2H).¹³C NMR (101 MHz, CDCl₃) δ 160.56, 160.01, 150.67, 136.86, 136.49, 134.32, 129.92, 128.85, 128.59, 127.51, 127.19, 123.62.

(49) 2-(3-bromophenyl)quinazoline (9i)⁶.



White solid; Mp.153-154 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.43 (s, 1H), 8.77 (t, J = 1.8 Hz, 1H), 8.54 (dt, J = 7.8, 1.3 Hz, 1H), 8.06 (d, J = 8.9 Hz, 1H), 7.95 – 7.85 (m, 2H), 7.61 (td, J = 7.1, 1.1 Hz, 2H), 7.38 (t, J = 7.9 Hz, 1H).¹³C NMR (101 MHz, CDCl₃) δ 160.57, 159.52, 150.62, 140.07, 134.35, 133.48, 131.58, 130.16, 128.67, 127.68, 127.17, 127.11, 123.74, 122.96.

(50) 2-(4-bromophenyl)quinazoline (9j)⁶.



White solid; Mp.120-121 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.32 (s, 1H), 8.39 (d, J = 8.6 Hz, 2H), 7.96 (d, J = 8.8 Hz, 1H), 7.81 (ddd, J = 7.3, 4.0, 2.3 Hz, 2H), 7.58 – 7.48 (m, 3H).¹³C NMR (101 MHz, CDCl₃) δ 160.55, 160.06, 150.65, 136.94, 134.31, 131.80, 130.16, 128.60, 127.52, 127.18, 125.44, 123.63.

(51) 2-(3-(trifluoromethyl)phenyl)quinazoline (9k)⁷.



Yellow solid; Mp.126-128 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.30 (s, 1H), 8.80 (s, 1H), 8.68 (d, J = 7.9 Hz, 1H), 7.95 (d, J = 9.1 Hz, 1H), 7.78 (ddd, J = 8.4, 6.2, 1.6 Hz, 2H), 7.63 (d, J = 7.7 Hz, 1H), 7.50 (q, J = 7.6 Hz, 2H).¹³C NMR (101 MHz, CDCl₃) δ 160.58, 159.44, 150.59, 138.80, 134.34, 131.68, 131.05 (q, J = 32.4 Hz), 129.06, 128.68, 128.36 (q, J = 271.0 Hz), 127.74, 127.14, 127.01 (q, J = 3.7 Hz), 125.47 (q, J = 3.9 Hz), 123.77.

(52) 2-(3-(trifluoromethyl)phenyl)quinazoline (91)⁶.



White solid; Mp.146-147 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.50 (s, 1H), 8.98 – 8.78 (m, 2H), 8.13 (d, J = 8.4 Hz, 1H), 8.00 – 7.93 (m, 2H), 7.77 (d, J = 7.8 Hz, 1H), 7.69 – 7.64 (m, 2H).¹³C NMR (101 MHz, CDCl₃) δ 160.64, 159.61, 150.66, 141.31, 134.41, 132.12 (q, J = 32.3 Hz), 129.09 128.84, 128.78, 127.89, 127.19, 125.53 (q, J = 3.9 Hz), 123.85.

(53) 2-(2-nitrophenyl)quinazoline (9m)⁸.



Yellow solid; Mp.91-92 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.44 (s, 1H), 8.13 (dd, J = 7.7, 1.5 Hz, 1H), 8.08 (d, J = 7.4 Hz, 1H), 8.00 – 7.93 (m, 2H), 7.90 (dd, J = 8.0, 1.2 Hz, 1H), 7.75 – 7.67 (m, 2H), 7.61 (td, J = 7.8, 1.5 Hz, 1H).¹³C NMR (101 MHz, CDCl₃) δ 160.55, 159.70, 150.43, 150.01, 134.61, 133.68, 132.31, 131.85, 130.18, 128.64, 128.34, 127.27, 124.17, 123.49.

(54) methyl 4-(quinazolin-2-yl)benzoate (9n)⁸.



Pale brown solid; Mp.120-121 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.38 (s, 1H), 8.62 – 8.57 (m, 2H), 8.14 – 8.08 (m, 2H), 8.01 (d, *J* = 9.3 Hz, 1H), 7.87 – 7.79 (m, 2H), 7.55 (td, *J* = 7.4, 1.1 Hz, 1H), 3.87 (s, 3H).¹³C NMR (101 MHz, CDCl₃) δ 166.96, 160.57, 159.98, 150.66, 142.12, 134.35, 132.25, 129.86, 128.77, 128.49, 127.82, 127.17, 123.75, 52.25.

(55) 2-(thiophen-2-yl)quinazoline (90)⁶.



White solid; Mp.137-138 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.34 (s, 1H), 8.15 (dd, J = 3.7, 1.2 Hz, 1H), 8.00 (d, J = 8.6 Hz, 1H), 7.91 – 7.84 (m, 2H), 7.58 – 7.53 (m, 1H), 7.52 (dd, J = 5.0, 1.3 Hz, 1H), 7.19 (dd, J = 5.0, 3.7 Hz, 1H).¹³C NMR (101 MHz, CDCl₃) δ 160.56, 157.88, 150.64, 143.86, 134.39, 129.98, 129.26, 128.42, 128.21, 127.30, 127.03, 123.39.

(56) 2-(furan-2-yl)quinazoline (9p)⁸.



Yellow solid; Mp.127-138 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.37 (d, J = 0.9 Hz, 1H), 8.13 – 8.07 (m, 1H), 7.91 – 7.85 (m, 2H), 7.69 (dd, J = 1.7, 0.9 Hz, 1H), 7.58 (td, J = 7.4, 1.1 Hz, 1H), 7.46 (dd, J = 3.4, 0.9 Hz, 1H), 6.62 (dd, J = 3.4, 1.7 Hz, 1H).¹³C NMR (101 MHz, CDCl₃) δ 160.74, 154.08, 152.50, 150.41, 145.36, 134.53, 128.36, 127.28, 123.36, 114.12, 112.35.

(57) 2-(pyridin-4-yl)quinazoline (9q)⁶.



Gray solid; Mp.134-135 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.35 (s, 1H), 8.69 (d, J = 6.1 Hz, 2H), 8.32 (d, J = 6.1 Hz, 2H), 7.98 (d, J = 8.8 Hz, 1H), 7.82 (ddd, J = 7.3, 4.0, 2.3 Hz, 2H), 7.56 (d, J = 8.1 Hz, 1H).¹³C NMR (101 MHz, CDCl₃) δ 160.68, 158.82, 150.48, 150.45, 145.23, 134.48, 128.82, 128.27, 127.15, 124.10, 122.30.

(58) 2-(naphthalen-2-yl)quinazoline (9r)⁸.



Yellow solid; Mp.133-134 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.35 (s, 1H), 9.04 (s, 1H), 8.62 (dd, J = 8.6, 1.7 Hz, 1H), 8.00 (d, J = 8.7 Hz, 1H), 7.95 – 7.91 (m, 1H), 7.87 (d, J = 8.7 Hz, 1H), 7.81 – 7.74 (m, 3H), 7.47 (d, J = 8.0 Hz, 1H), 7.44 – 7.39 (m, 2H).¹³C NMR (101 MHz, CDCl₃) δ 161.00, 160.53, 150.83, 135.41, 134.72, 134.19, 133.45, 129.32, 129.00, 128.65, 128.33, 127.77, 127.32, 127.19, 127.14, 126.27, 125.47, 123.64.

9. NMR spectra of obtained compounds

٠N 2

¹H NMR, 400 Hz







2 ¹³C NMR, 101Hz





-5.36 -5.36 -5.36 -4.18 -3.40 -3.40 -3.40













−5.82 −5.82 −5.82 −5.82 −5.82 −3.418 −3.43 −3.43























-163.11 -161.25 -161.25 -161.25 -141.2









-5.50 -5.50






































S42













































¹H NMR, 400 Hz













-3.11

 $\substack{ < \frac{7.30}{7.28} \\ < \frac{6.91}{6.89} \\ < 6.89 \\ \end{cases}$











7i ¹³C NMR, 101 Hz



























¹H NMR, 400 Hz







200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -1 f1 (ppm)









¹³C NMR 101 Hz Me





S64





-55.40























200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -1 fl (ppm)











9, 35 9, 35 9, 35 9, 35 9, 3, 35 9, 3, 44 9, 44 9, 44 9, 44 9, 44 9, 44 9, 44 9, 44 1, 55 1, 55









-9.43 -9.43 -8.77 -8.55 -8.55 -8.55 -8.55 -8.55 -8.55 -8.55 -8.55 -8.55 -8.55 -8.55 -8.55 -8.55 -8.55 -8.55 -7.79 -7.79 -7.79 -7.79 -7.79 -7.79 -7.79 -7.79 -7.79 -7.755 -7.7555 -7.7555 -7.7555 -7.7555 -7.7555 -7.7555 -7.7555 -7.7555 -7.7555 -7.







-9.32 (8.40) (8.41) (7.79) (7.79) (7.79) (7.79) (7.79) (7.79) (7.79) (7.79) (7.79) (7.77) (7.79) (7.77) (7.77) (7.76) (7.77) (7.75) (7.









S71














¹³C NMR 101 Hz











¹³C NMR 101 Hz







-9.34 -9.34 -9.16 -9.16 -9.16 -9.17 -9.17 -9.17 -1.25 -1.75



11110112



1160.56 1157.88 1150.64 143.86 1134.39 1134.39 1134.39 1129.26 1129.26 1129.26 1128.42 1127.30 1127.03



¹³C NMR 101 Hz



10 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -1 f1 (ppm)





-160.74 154.08 152.50 152.50 145.36 -145.36 -145.36 -123.36 -123.36 -123.36 -123.36



9p ¹³C NMR 101 Hz





¹H NMR 400 Hz





79.35 79.04 79.04 78.63 78.63 78.61 79.86 71.79 71.79 71.79 71.77 71.78 71.77 71.78 71.77 71.78 71.77 71.78 71.77 71.78 71.77 71.78 71.77 71.74 71.777





161.00 160.53 156.41 135.41 135.41 133.45 129.32 129.32 129.32 129.32 129.32 129.32 129.32 129.32 127.14 127.13 127.13 126.27 126.27 126.27 126.27 126.27 126.27 126.27 126.27 126.27 126.27 126.27 126.33 127.32 127.32 127.32 127.33 126.33 127.32 127.32 127.33



¹³C NMR 101 Hz



10 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -1 f1 (ppm)

11. Reference

- (1) W. Yao, Y. Zhang, H. Zhu, C. Ge and D. Wang, Chin. Chem. Lett., 2020, 31, 701.
- (2) A. E. Putra, Y. Oe and T. Ohta, Eur. J. Org. Chem., 2018, 2018, 392.
- (3) A. E. Putra, Y. Oe and T. Ohta, *Tetrahedron Lett.*, 2017, 58, 1098.
- (4) E. Fillion, A. Kavoosi, K. Nguyen and C. Ieritano, Chem. Commun., 2016, 52, 12813-.
- (5) D. Deka and S. Kalita, *Synlett*, 2017, **29**, 477.
- (6) S. Parua, R. Sikari, S. Sinha, G. Chakraborty, R. Mondal and N. D. Paul, J. Org. Chem., 2018, 83, 11154.
- (7) G. R. Y. Kumar and N. S. Begum, New J. Chem., 2021, 45, 9811.
- (8) R. Gujjarappa, S. K. Maity, C. K. Hazra, N. Vodnala, S. Dhiman, A. Kumar, U. Beifuss and C. C. Malakar, *Eur. J. Org. Chem.*, 2018, 2018, 4628.